COMBINATION THERAPY WITH ANTICANCER ALKALOID Russian patent published in 2022 - IPC A61K31/34 A61K31/395 A61K31/4995 A61P35/00 

FIELD: pharmaceutical industry.

SUBSTANCE: group of inventions relates to the use of a therapeutically effective amount of PM01183 or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of a topoisomerase I and/or II inhibitor for treating cancer. Use of a therapeutically effective amount of PM01183 or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of a topoisomerase I and/or II inhibitor for treating cancer, where the topoisomerase I and/or II inhibitor is topotecan, when the cancer to be treated is selected from lung cancer, malignant melanoma, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, hepatoma, colorectal cancer, kidney cancer and brain cancer, and wherein the topoisomerase I and/or II inhibitor is irinotecan, when the cancer to be treated is selected from lung cancer, malignant melanoma, prostate cancer, pancreatic cancer, ovarian cancer and breast cancer. Use of a therapeutically effective amount of PM01183 or a pharmaceutically acceptable salt thereof in a combination with a therapeutically effective amount of a topoisomerase I and/or II inhibitor in the manufacture of a drug for treating cancer, where the topoisomerase I and/or II inhibitor is topotecan, when the cancer to be treated is selected from lung cancer, malignant melanoma, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, hepatoma, colorectal cancer, kidney cancer and brain cancer, and wherein the topoisomerase I and/or II inhibitor is irinotecan, when the cancer to be treated is selected from lung cancer, malignant melanoma, prostate cancer, pancreatic cancer, ovarian cancer and breast cancer.

EFFECT: application described above synergistically increases efficacy of therapeutic treatment of cancer.

6 cl, 296 dwg, 26 tbl, 19 ex